title: An empirical approach towards the efficient and optimal production of influenza-neutralizing ovine polyclonal antibodies demonstrates that the novel adjuvant CoVaccine HT™ is functionally superior to Freund's adjuvant.
abstract: Passive immunotherapies utilising polyclonal antibodies could have a valuable role in preventing and treating infectious diseases such as influenza, particularly in pandemic situations but also in immunocompromised populations such as the elderly, the chronically immunosuppressed, pregnant women, infants and those with chronic diseases. The aim of this study was to optimise current methods used to generate ovine polyclonal antibodies. Polyclonal antibodies to baculovirus-expressed recombinant influenza haemagglutinin from A/Puerto Rico/8/1934 H1N1 (PR8) were elicited in sheep using various immunisation regimens designed to investigate the priming immunisation route, adjuvant formulation, sheep age, and antigen dose, and to empirically ascertain which combination maximised antibody output. The novel adjuvant CoVaccine HT™ was compared to Freund's adjuvant which is currently the adjuvant of choice for commercial production of ovine polyclonal Fab therapies. CoVaccine HT™ induced significantly higher titres of functional ovine anti-haemagglutinin IgG than Freund's adjuvant but with fewer side effects, including reduced site reactions. Polyclonal hyperimmune sheep sera effectively neutralised influenza virus in vitro and, when given before or after influenza virus challenge, prevented the death of infected mice. Neither the age of the sheep nor the route of antigen administration appeared to influence antibody titre. Moreover, reducing the administrated dose of haemagglutinin antigen minimally affected antibody titre. Together, these results suggest a cost effective way of producing high and sustained yields of functional ovine polyclonal antibodies specifically for the prevention and treatment of globally significant diseases.
authors.affiliation: Experimental Therapeutics Laboratory, Hanson Institute, Adelaide, SA, Australia.
authors.forename: Natalie E
authors.initials: NE
authors.lastname: Stevens
authors.forename: Cara K
authors.initials: CK
authors.lastname: Fraser
authors.forename: Mohammed
authors.initials: M
authors.lastname: Alsharifi
authors.forename: Michael P
authors.initials: MP
authors.lastname: Brown
authors.forename: Kerrilyn R
authors.initials: KR
authors.lastname: Diener
authors.forename: John D
authors.initials: JD
authors.lastname: Hayball
mesh_terms: D000276:Adjuvants, Immunologic; D000375:Aging / Q000276:immunology; D000818:Animals; D057134:Antibodies, Neutralizing / Q000096:biosynthesis* / Q000276:immunology; D000914:Antibodies, Viral / Q000096:biosynthesis* / Q000276:immunology; D004306:Dose-Response Relationship, Immunologic; D005260:Female; D005620:Freund's Adjuvant / Q000276:immunology*; D019267:Hemagglutinin Glycoproteins, Influenza Virus / Q000276:immunology; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000276:immunology*; D007274:Injections, Intraperitoneal; D007279:Injections, Subcutaneous; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000517:prevention & control; D012756:Sheep; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology
chemical_list: D000276:Adjuvants, Immunologic; D057134:Antibodies, Neutralizing; D000914:Antibodies, Viral; D019267:Hemagglutinin Glycoproteins, Influenza Virus; D007252:Influenza Vaccines; D014614:Vaccines, Synthetic; D005620:Freund's Adjuvant
references.citation: J Immunol. 1973 Jul;111(1):114-20
references.pmid: 4713290
references.citation: Immunotherapy. 2012 Feb;4(2):175-86
references.pmid: 22339460
references.citation: Parasitol Res. 2006 Jan;98(2):119-29
references.pmid: 16292678
references.citation: PLoS One. 2010 Oct 26;5(10):e13622
references.pmid: 21049034
references.citation: J Immunol. 1992 Sep 15;149(6):1905-11
references.pmid: 1517561
references.citation: Curr Protoc Neurosci. 2009 Jul;Chapter 5:Unit 5.5
references.pmid: 19575471
references.citation: Biochim Biophys Acta. 2007 Feb;1774(2):200-12
references.pmid: 17236828
references.citation: Int J Antimicrob Agents. 2012 Jul;40(1):72-4
references.pmid: 22591839
references.citation: Clin Chem. 2002 Sep;48(9):1580-4
references.pmid: 12194938
references.citation: Antimicrob Agents Chemother. 2012 Aug;56(8):4046-51
references.pmid: 22615289
references.citation: Biotechnol Appl Biochem. 2005 Oct;42(Pt 2):163-8
references.pmid: 15799716
references.citation: Vaccine. 2012 Jul 13;30(33):5009-18
references.pmid: 22658967
references.citation: Vaccine. 2012 Jul 27;30(35):5262-9
references.pmid: 22691431
references.citation: Influenza Other Respir Viruses. 2011 May;5(Suppl 1):226-9
references.pmid: 21761590
references.citation: Vaccine. 2001 Mar 21;19(17-19):2666-72
references.pmid: 11257407
references.citation: Curr Opin Gastroenterol. 2012 May;28(3):198-202
references.pmid: 22450893
references.citation: N Biotechnol. 2011 Sep;28(5):489-501
references.pmid: 21473942
references.citation: J Immunol. 2011 Sep 1;187(5):2602-16
references.pmid: 21813775
references.citation: Vaccine. 1997 Feb;15(3):248-56
references.pmid: 9139482
references.citation: Vaccine. 2009 Oct 30;27(46):6424-31
references.pmid: 19549607
references.citation: Pediatr Infect Dis J. 2011 Jan;30(1):67-9
references.pmid: 20724956
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Mar 15;848(1):2-7
references.pmid: 16893686
references.citation: Immunol Rev. 1997 Apr;156:199-209
references.pmid: 9176709
references.citation: Biotechnol Appl Biochem. 2008 Oct;51(Pt 2):79-90
references.pmid: 18205624
references.citation: Immunol Today. 2000 Dec;21(12):624-30
references.pmid: 11114423
references.citation: Clin Vaccine Immunol. 2012 Feb;19(2):209-18
references.pmid: 22190392
references.citation: Vaccine. 2011 May 12;29(21):3791-801
references.pmid: 21439319
references.citation: Comp Immunol Microbiol Infect Dis. 2009 Jan;32(1):9-19
references.pmid: 18242705
references.citation: Virol J. 2011 Nov 04;8:506
references.pmid: 22054309
references.citation: J Virol. 2010 Aug;84(16):7943-52
references.pmid: 20519384
references.citation: Antiviral Res. 2011 Sep;91(3):252-8
references.pmid: 21722671
references.citation: Acta Clin Belg. 2012 Jan-Feb;67(1):1-6
references.pmid: 22480031
references.citation: Vaccine. 2011 Nov 8;29(48):8888-97
references.pmid: 21963871
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Jan 25;814(2):209-15
references.pmid: 15639441
references.citation: PLoS Pathog. 2010 Feb 26;6(2):e1000796
references.pmid: 20195520
references.citation: Curr HIV Res. 2003 Jul;1(3):309-20
references.pmid: 15046255
references.citation: Immunol Cell Biol. 2010 May-Jun;88(4):376-80
references.pmid: 20309010
references.citation: Curr Biol. 2009 May 12;19(9):R355-61
references.pmid: 19439254
references.citation: Vaccine. 2009 Nov 16;27(49):6833-9
references.pmid: 19772942
references.citation: J Med Toxicol. 2011 Mar;7(1):44-6
references.pmid: 20658221
references.citation: PLoS One. 2011;6(5):e20547
references.pmid: 21655233
references.citation: Immunol Rev. 2011 Jan;239(1):167-77
references.pmid: 21198671
references.citation: Immunity. 2008 Sep 19;29(3):497-510
references.pmid: 18789730
references.citation: Immunity. 2003 Aug;19(2):225-34
references.pmid: 12932356
references.citation: Expert Rev Vaccines. 2012 Apr;11(4):461-8
references.pmid: 22551031
references.citation: ILAR J. 2005;46(3):269-79
references.pmid: 15953834
references.citation: Adv Drug Deliv Rev. 1998 Jul 6;32(3):173-186
references.pmid: 10837643
references.citation: J Clin Invest. 2010 May;120(5):1663-73
references.pmid: 20389023
references.citation: Toxicon. 1994 Apr;32(4):427-33
references.pmid: 8052997
references.citation: J Immunol. 2010 Dec 15;185(12):7583-95
references.pmid: 21098232
references.citation: mBio. 2012 May 29;3(3):
references.pmid: 22647789
references.citation: Vaccine. 2004 Dec 21;23(6):743-54
references.pmid: 15542198
references.citation: Expert Rev Vaccines. 2007 Aug;6(4):559-78
references.pmid: 17669010
references.citation: Bull World Health Organ. 1967;37(5):729-36
references.pmid: 5300875
references.citation: Vaccine. 2012 Mar 9;30(12):2060-7
references.pmid: 22289511
references.citation: Infect Immun. 1995 Jan;63(1):99-103
references.pmid: 7806391
references.citation: Endoscopy. 2011;43 Suppl 2 UCTN:E261
references.pmid: 21837605